Cargando…
Toxicological Studies of (212)Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial
Faced with the novelty of a (212)Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding (212)Pb prematurely released from the mAb-chelate conjugate. The objective of this study was to simulate the worst case scenario...
Autores principales: | Milenic, Diane E., Molinolo, Alfredo A., Solivella, María S., Banaga, Eileen, Torgue, Julien, Besnainou, Sarah, Brechbiel, Martin W., Baidoo, Kwamena E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588175/ https://www.ncbi.nlm.nih.gov/pubmed/26213947 http://dx.doi.org/10.3390/ph8030416 |
Ejemplares similares
-
Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and (212)Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model
por: Yong, Kwon Joong, et al.
Publicado: (2016) -
Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
por: Yong, Kwon J, et al.
Publicado: (2013) -
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With (212)Pb-TCMC-Trastuzumab
por: Meredith, Ruby F., et al.
Publicado: (2018) -
Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts
por: Yong, Kwon Joong, et al.
Publicado: (2016) -
(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
por: Yong, K J, et al.
Publicado: (2013)